Cancer - Prostate(구연) (E-145) 비전이성 거세저항성 전립선암 환자에서 거세저항상태까지 이르는 시간과 전이까지 이르는 시간에 대한 영향에 대한 분석 ; 전향적 단일 기관 연구 아주대학교 의과대학 비뇨기과학 교실 박성곤, 심강희, 유희재, 김선일, 추설호, 김세중, 안현수, 최종보 Introduction nmCRPC is a disease that has been studied a lot recently, and it is known that enzalutamide, etc., has an important effect on metastasis through SPARTAN study. However, the number of nmCRPC patients is less than that of mCRPC patients and there is less research, so information about nmCRPC is still insufficient. We conducted this retrospective single center study to see how many nmCRPCs were diagnosed and characterized in clinical practice. Patient and methods We collected data of patients diagnosed with CRPC at Ajou University Hospital from 1994 to 2019, and classified nmCRPC patients with mCRPC patients through data analysis. We used the T test to see how the clinical features such as age, GS, PSA, clinical T, and N stage differ in both groups. Also, the time from diagnosis to CRPC state was compared by T-test. We analyzed time to metastasis (TTM) from CRPC state of nmCRPC patients. Cox regression analysis was used to analyze factors affecting TTM. We used SPSS 22 version. Results We reviewed a total of 152 CRPC patients, 51 patients were nmCRPC. The mean time from diagnosis to CRPC in nmCRPC patients was 60 months, and that of mCRPC patients was significantly different at 23 months. There were also significant differences in prebiopsy PSA, GS, clinical T stage, and LN except age. In 51 nmCRPC patients, 11 had no metastasis during the follow-up period, and 40 had metastasis eventually. The mean time to metastasis of 40 patients was 15 months and the median was 9 months. In cox regression analysis, the only dose of estramustine immediately after CRPC diagnosis was significant for delaying TTM, whereas age, GS, T stage, LN, prebiopsy PSA, initial treatment and the duration of ADT, the time from diagnosis to CRPC was not. HR was 7.1 (95% CI 2.4 -20.9) when estramustine was not started immediately. Conclusion This study confirmed how many nmCRPCs are in a single center and what characteristics they have. It was confirmed that the time to CRPC differed by 3 years compared to mCRPC. We found that treatment with estramustine immediately after diagnosis of CRPC had a greater effect on TTM than in the previous status of cancer such as GS, PSA, stage, etc., when CRPC status was reached. Even in the post enzalutamide era, accurately diagnosis of CRPC and starting medication immediately seems to be the most important way to delay metastasis keywords : prostate, nonmetastic castration resistant prostate cancer